Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21839711 | 1.00 | NT5E (0.33) | NT5EALDH1A1RXFP1PRMT5WDR77 | |
| SCHEMBL21839614 | 0.90 | NT5E (0.37) | NT5EALDH1A1RXFP1PRMT5WDR77 | |
| SCHEMBL21883347 | 0.90 | NT5E (0.37) | NT5EALDH1A1RXFP1PRMT5WDR77 | |
| SCHEMBL31526129 | 0.89 | RXFP1 (0.33) | RXFP1 | |
| SCHEMBL21883346 | 0.84 | NT5E (0.32) | NT5E | |
| SCHEMBL21839494 | 0.84 | NT5E (0.32) | NT5E | |
| SCHEMBL18572819 | 0.81 | PRMT5 (0.34) | NT5EALDH1A1RXFP1PRMT5WDR77 | |
| SCHEMBL22975448 | 0.80 | ADORA3 (0.39) | NT5E | |
| SCHEMBL18572203 | 0.80 | RXFP1 (0.34) | NT5EALDH1A1RXFP1PRMT5WDR77 | |
| SCHEMBL31526303 | 0.79 | RXFP1 (0.39) | NT5ERXFP1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | PELOTON THERAPEUTICS INC. | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115404-A1 | CD73 INHIBITORS AND USES THEREOF | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ALDH1A1 587/4885RXFP1 1796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.